Spring Health Launches Integrated Critical Incident Response to Help Companies Navigate Crisis with Confidence and Compassion
New longitudinal approach delivers real-time transparency, in-house trauma-informed providers, and ongoing support beyond the event to redefine workplace crisis care.
NEW YORK, April 29, 2025 /PRNewswire/ -- Spring Health, a complete global mental health solution for employers and health plans, has launched Integrated Critical Incident Response—a comprehensive approach to crisis response that empowers HR leaders to support their organizations with clarity and effective support when it matters most.
As critical incidents grow in frequency and visibility, HR leaders are under mounting pressure to respond with both precision and compassion. Yet most are left navigating these high-stakes moments with outdated tools, limited insight, and short-lived support. Spring Health's Integrated Critical Incident Response sets a new standard—offering the industry's first fully integrated, longitudinal solution built within a high-quality mental health platform.
Unlike traditional models, Spring Health offers a modern, tech-enabled approach to critical incident response, including:
'Most crisis response services are designed to check a box—they show up, hold a session, and disappear,' said Gijo Mathew, Chief Product Officer at Spring Health. 'We created Integrated Critical Incident Response to offer something different—a modernized approach to give HR leaders a solution they can trust, and employees the kind of support that doesn't end when the headlines fade. It's about being there for the full journey, not just the first 24 hours.'
'A single conversation after a crisis isn't enough to drive real recovery or restore a sense of safety,' said Dr. Mill Brown, Chief Medical Officer at Spring Health. 'The therapeutic process takes time, trust, and consistent support. Our model is built to provide exactly that—longitudinal care from trauma-informed experts who stay engaged well beyond the initial response. We're not just addressing the moment of crisis—we're guiding people through the full arc of recovery with compassion, structure, and clinical excellence.'
Spring Health's approach is grounded in the latest trauma science and delivers tools built for clinical impact and everyday usability. The model moves beyond one-time interventions to offer sustained care that helps employees and leaders navigate the full recovery journey. Integrated Critical Incident Response equips every individual touched by a workplace crisis with the tools they need to move forward.
Learn more by visiting our website here.
About Spring Health
Spring Health is a complete global mental health solution for employers and health plans. By integrating products for members, providers, and customers, Spring Health uniquely delivers personalized care for every individual—ranging from digital tools and meditation to coaching, therapy, and medication—ensuring the right care at the right time. Certified by JAMA Network Open and the Validation Institute for demonstrating net savings for customers, Spring Health also equips global business leaders with intelligent technology, real-time insights, and clinical expertise to support diverse and evolving organizational needs.
Today, more than 20 million people worldwide have access to Spring Health. We're trusted by leading employers, health plans and channel partners, including Adobe, Bumble, General Mills, Moda Health, Wellstar, and Guardian, to drive cultural impact at scale. For more information, please visit https://www.springhealth.com.
Media Contact
5WPR
[email protected]
View original content to download multimedia: https://www.prnewswire.com/news-releases/spring-health-launches-integrated-critical-incident-response-to-help-companies-navigate-crisis-with-confidence-and-compassion-302440560.html
SOURCE Spring Health
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
9th Asia Agri-Tech Expo & Forum Opens Today, Driving Innovation in Asia-Pacific Agriculture
TAIPEI, June 11, 2025 /PRNewswire/ -- Organised by Informa Markets Asia Ltd., the 2025 Asia Agri-Tech Expo & Forum officially opened today (June 11) at the ICC Tainan. The grand opening ceremony gathered key representatives from government, industry, academia, and research to witness a new milestone in the advancement of agri-tech in the Asia-Pacific region. Distinguished guests attending the ribbon-cutting ceremony included Mr. Michael Duck, Executive Vice President of Informa Markets Asia, Deputy Mayor Yeh Tse-Shan of Tainan City Government, President Su Chih-Fen of the National Animal Industry Foundation, along with numerous prominent figures from various sectors. This year's event features over 150 exhibitors from around the world, showcasing cutting-edge innovations in agriculture automation, smart livestock farming, precision irrigation, crop monitoring, and feed technology. In addition to the exhibition, the event presents 10 key themes across 60 professional seminars, offering in-depth discussions on emerging trends in agriculture, smart livestock farming, advanced feed technology, and biosecurity upgrades. The three-day exhibition is expected to attract over 25,000 visitors. With Tainan serving as a central hub for agriculture and aquaculture in southern Taiwan, the event provides an ideal platform for farmers, growers, and industry professionals to explore the latest advancements. Many exhibitors are launching new products on-site, including: TOTAL NUTRITION: Combining peptide protein, probiotics, and acidifiers to form the "Golden Triangle" of gut health, achieving precise nutritional regulation and enhanced well-being. WONDER VAX: Introducing the Universal Live Vaccine for Infectious Bronchitis in Chickens (TW-I, TW-II), providing dual protection against respiratory and nephritis strains, precisely targeting Taiwan's prevalent local strains (TW-I, TW-II). YA SUH DAR: Launching a 50-inch butterfly shutter exhaust fan specifically designed for livestock farming. This large negative-pressure fan features an innovative pneumatic butterfly shutter design that effectively replaces traditional louver windows, significantly improving ventilation efficiency. It also offers excellent dustproof, corrosion-resistant, and weather-resistant performance, making it ideal for harsh environments with high temperatures and humidity. VETNOSTRUM: Comprehensive range of veterinary medicines, health products, feed additives, and feeds for pigs, cattle, sheep, poultry, and aquatic animals. AGRISTAR: Asia's first fully electric tractor, manufactured by Foxconn in the U.S., featuring Tesla technology and NVIDIA AI computing. Compatible with a variety of agricultural implements, it serves not only in dairy farming but also in a wide range of daily agricultural and livestock operations. This next-generation farming equipment paves the way for a net-zero carbon, sustainable agricultural future. Ms. Grace Lee, General Manager of Informa Markets Taiwan, stated: "Taiwan's agricultural sector boasts strong technological capabilities. Through this international platform, we foster knowledge exchange and drive innovation, enhancing global food self-sufficiency where Taiwan will play an increasingly pivotal role." The expo runs from June 11 to 13, open to industry professionals and related personnel free of charge. The organizers aim to foster cross-border collaboration and create a prosperous future for Asia-Pacific agriculture, paving the way for the next century of agricultural innovation. View original content to download multimedia: SOURCE Informa Markets Asia Ltd., Taiwan Branch Sign in to access your portfolio
Yahoo
3 hours ago
- Yahoo
Joan Schwartz releases 'Divine Healing: Ancient Secrets of Our Ancestors'
New book bridges science and spirituality with the Integrated Healing Dynamics Method for self-guided mind-body-spirit healing RIVERTON, Utah, June 11, 2025 /PRNewswire-PRWeb/ -- First-time author Joan Schwartz marks her entry into publishing with the release of "Divine Healing: Ancient Secrets of Our Ancestors" (published by Balboa Press). Blending ancient spiritual insight with contemporary scientific understanding, this book introduces the Integrated Healing Dynamics (IHD) Method — a holistic, accessible healing framework designed to awaken the innate power within every individual. Rooted in a vision that first appeared to her in 1988, Schwartz says the inspiration for "Divine Healing" came through higher guidance. "I had a revelation and saw the book from beginning to end," she recalls. "Later, I was given direction to write a healing book so that if people couldn't get a session or help from me, they could heal themselves." "Divine Healing: Ancient Secrets of Our Ancestors" is a complete healer's resource that empowers readers with the knowledge and techniques to realign their energy, awaken their body's natural healing systems, and cultivate peace, joy, and self-love. The IHD Method taught in the book is the culmination of a lifetime of spiritual dialogue and deep intuitive knowing. Through its simple, step-by-step exercises and guiding principles, readers are invited to remove the "mask" that blocks them from their true essence — and step into their divine right to healing. "Healing is not just about the body; it is about the mind and spirit too," the author reminds. From relieving physical pain to addressing emotional wounds and spiritual imbalances, "Divine Healing: Ancient Secrets of Our Ancestors" offers a practical roadmap to transformation. To get a copy and learn more, visit "Divine Healing: Ancient Secrets of Our Ancestors" By Joan Schwartz Hardcover | 6 x 9in | 836 pages | ISBN 9798765255186 Softcover | 6 x 9in | 836 pages | ISBN 9798765255162 E-Book | 836 pages | ISBN 9798765255179 Available at Amazon and Barnes & Noble About the Author Joan Schwartz is a seasoned hypnotherapist and integrative healer with decades of experience in energy work, clinical hypnotherapy, and alternative healing. Her journey began in childhood with a deep sensitivity to unseen energies and was shaped by transformative life events, including a pivotal car accident in 1965 and a near-fatal brain hemorrhage. With a Ph.D. in Alternative Healing, Clinical Hypnotherapy and Philosophy, Schwartz blends science and spirituality to empower others in unlocking their healing potential. She is passionate about helping individuals live peaceful, fulfilling lives through self-discovery and holistic healing practices. Balboa Press, a division of Hay House, Inc. – a leading provider in publishing products that specialize in self-help and the mind, body, and spirit genres. Through an alliance with the worldwide self-publishing leader Author Solutions, LLC, authors benefit from the leadership of Hay House Publishing and the speed-to-market advantages of the self-publishing model. For more information, visit To start publishing your book with Balboa Press, call 844-682-1282 today. Media Contact Marketing Services, BalboaPress, 844-682-1282, pressreleases@ View original content to download multimedia: SOURCE BalboaPress
Yahoo
4 hours ago
- Yahoo
Kelun-Biotech Announces Breakthrough Therapy Designation Granted for Sacituzumab Tirumotecan (Sac-TMT) in Combination With Tagitanlimab in China for Certain Types of Non-Small Cell Lung Cancer
CHENGDU, China, June 10, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") today announced that its TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) (佳泰莱®) in combination with the PD-L1 monoclonal antibody tagitanlimab (科泰莱®) was granted Breakthrough Therapy Designation by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China for the first-line treatment of locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) without actionable genomic alterations. Breakthrough Therapy Designation is granted for treatment options that demonstrate significant clinical advantages over currently available treatments and is aimed at expediting the research, development and marketing of innovative treatment options that address clinically urgent medical needs. This designation is based on the efficacy and safety data from the non-squamous cohort of the Phase II OptiTROP-Lung01 study. This marks the fifth Breakthrough Therapy Designation granted to sac-TMT by the NMPA. Sac-TMT has previously received this designation for: Locally advanced or metastatic triple-negative breast cancer (TNBC) in July 2022; EGFR-mutant, locally advanced or metastatic NSCLC after progression on EGFR-TKI therapy in January 2023; Locally advanced or metastatic hormone-receptor positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer (BC) in patients who have previously received at least two lines of systemic chemotherapy in June 2023； First-line treatment of unresectable locally advanced, recurrent or metastatic PD-L1 negative TNBC in March 2024. Results from a Phase 2 OptiTROP-Lung01 study of sac-TMT in combination with tagitanlimab in first-line advanced or metastatic non-squamous NSCLC patients were presented in a poster session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting[1]. Dr. Michael Ge, CEO of Kelun-Biotech said, "This designation by the NMPA highlights the importance of developing novel therapeutic options for diverse NSCLC subtypes. Sac-TMT in combination with tagitanlimab demonstrated clinically meaningful outcomes in key endpoints for patients with non-squamous NSCLC without actionable genomic alterations as a first-line treatment. We are excited about the therapeutic potential of TROP2 ADC- immunotherapy combinations, and we look forward to working with regulatory authorities in China to bring this combination therapy to patients in need as soon as possible." [1] Abstract #8529: Lung Cancer – Non-Small Cell Metastatic, ASCO Annual Meeting, 2025 About sac-TMT (佳泰莱®)Sac-TMT, a core product of the Company, is a novel human TROP2 ADC in which the Company has proprietary intellectual property rights, targeting advanced solid tumors such as NSCLC, BC, gastric cancer (GC), gynecological tumors, among others. Sac-TMT is developed with a novel linker to conjugate the payload, a belotecan-derivative topoisomerase I inhibitor with a drug-to-antibody-ratio (DAR) of 7.4. Sac-TMT specifically recognizes TROP2 on the surface of tumor cells by recombinant anti-TROP2 humanized monoclonal antibodies, which is then endocytosed by tumor cells and releases KL610023 intracellularly. KL610023, as a topoisomerase I inhibitor, induces DNA damage to tumor cells, which in turn leads to cell-cycle arrest and apoptosis. In addition, it also releases KL610023 in the tumor microenvironment. Given that KL610023 is membrane permeable, it can enable a bystander effect, or in other words kill adjacent tumor cells. In May 2022, the Company licensed the exclusive rights to MSD (the tradename of Merck & Co., Inc., Rahway, NJ, USA) to develop, use, manufacture and commercialize sac-TMT in all territories outside of Greater China (includes Mainland China, Hong Kong, Macao, and Taiwan). To date, two indications for sac-TMT have been approved and marketed in China for the treatment of adult patients with unresectable locally advanced or metastatic TNBC who have received at least two prior systemic therapies (at least one of them for advanced or metastatic setting) and EGFR mutation-positive locally advanced or metastatic non-squamous NSCLC following progression on EGFR-TKI therapy and platinum-based chemotherapy. Sac-TMT became the first domestic ADC with global intellectual property rights to be fully approved for marketing. It is also the world's first TROP2 ADC to be approved for marketing in a lung cancer indication. In addition, two new indication applications for sac-TMT for the treatment of adult patients with EGFR-mutant locally advanced or metastatic NSCLC who progressed after treatment with EGFR-TKI therapy and with unresectable locally advanced, metastatic HR+/HER2- BC who have received prior endocrine therapy and other systemic treatments in the advanced or metastatic setting were accepted by the CDE, and were included in the priority review and approval process. As of today, the Company has initiated 8 registrational clinical studies in China. MSD has initiated 14 ongoing Phase 3 global clinical studies of sac-TMT as a monotherapy or with pembrolizumab2 or other agents for several types of cancer. These studies are sponsored and led by MSD. About Tagitanlimab (科泰莱®)Tagitanlimab is the first PD-L1 mAb globally to receive authorization for the first-line treatment of NPC. Previously, the NMPA has approved the marketing in China of tagitanlimab used in combination with cisplatin and gemcitabine for the first-line treatment of patients with R/M NPC and monotherapy for the treatment of patients with recurrent or metastatic NPC who have failed after prior 2L+ chemotherapy, respectively. About Kelun-BiotechKelun-Biotech ( is a holding subsidiary of Kelun Pharmaceutical ( which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. The company focuses on major disease areas such as solid tumors, autoimmune, inflammatory, and metabolic diseases, and in establishing a globalized drug development and industrialization platform to address the unmet medical needs in China and the rest of world. The Company is committed to becoming a leading global enterprise in the field of innovative drugs. At present, the Company has more than 30 ongoing key innovative drug projects, of which 3 projects have been approved for marketing, 1 project is in the NDA stage, and more than 10 projects are in the clinical stage. The company has established one of the world's leading proprietary ADC platforms, OptiDC™, and has 1 ADC project approved for marketing, 1 ADC project in NDA stage, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please visit Media: klbio_pr@ View original content to download multimedia: SOURCE Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
